Boosting CAR T Cell Therapy for Solid Tumors

Katie McKenna will discuss how oncolytic viral therapy enhances CAR-T cell killing of cancer cells.

The Scientist Creative Services Team in Collaboration with IsoPlexis
Apr 5, 2021

FREE Webinar

Tuesday, April 27, 2021
2:30 - 3:30 PM, Eastern Time

Register Now

Chimeric antigen receptor (CAR) T cells hold great promise for targeting and fighting cancer. However, their efficacy in solid tumors has been below expectations, as the tumor microenvironment (TME) limits their infiltration and produces a range of immune-inhibitory molecules to deactivate T cells. Researchers are developing new strategies to enhance CAR-T cell therapy for solid tumors by disrupting the TME and promoting T cell persistence. In this webinar brought to you by IsoPlexis, Katie McKenna will discuss how she uses CAR-T cells in combination with mesenchymal stromal cells that deliver engineered adenoviruses to stimulate the immune response in the TME.  

Topics to be covered

  • Targeting non-small cell lung cancer using a cell carrier system to deliver an oncolytic and immunostimulatory adenovirus
  • Efficacy of oncolytic virotherapy in 3D cell culture and in vivo
  • Assessing T cell functionality with single-cell proteomics

Register Now

Meet the speaker

Katie McKenna, PhD
Postdoctoral Fellow
Center for Cell and Gene Therapy
Baylor College of Medicine
Texas Children’s Hospital
Methodist Hospital